Avanir Pharmaceuticals Announces Positive Phase II Trial Results For AVP-923 In Treatment Of Agitation In Patients With Alzheimer's Disease
September 15, 2014 at 08:33 AM EDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced positive results from its phase II clinical trial evaluating the safety and ...